2022, Number 2
<< Back Next >>
Rev CONAMED 2022; 27 (2)
Identification of useful commercial PCR tests to detect SARS-CoV-2 viruses at the Institute of Epidemiological Diagnosis and Reference during the first year of the COVID-19 pandemic in Mexico
Gómez PC, Guzmán BC, Gordillo MM, Ramírez GJE, Hernández RL, López MI, Barrera BG, Escobar EN, Olivera DH, Grupo E
Language: Spanish
References: 25
Page: 68-79
PDF size: 216.88 Kb.
ABSTRACT
Since the initial phase of the spread of the SARS-CoV-2 virus in Wuhan, China, the etiological confirmation of cases of acute respiratory infection has been carried out through the identification of viral RNA mainly through real-time RT-PCR tests. Since the appearance of the first case outside China in January 2020, one of the first molecular techniques for the identification of the new coronavirus worldwide has been standardized at InDRE (the national reference laboratory for epidemiological surveillance in Mexico). Later, as of February 3, the InDRE and the National Network of Public Health Laboratories implemented one of the tests recommended by the WHO for diagnosis throughout the country. In mid-March, as part of the diagnostic response during the contingency, the InDRE began the preliminary evaluation of molecular diagnostic tests in the process of being introduced to the commercial market in the country. The evaluation consists of the laboratory verification of the specific analytical criteria defined by the manufacturers. As of March 2021, 84 useful PCR tests have been identified, included in a list available on the official website of the Ministry of Health. These are high-performance products that support the supply and demand of commercial tests with good analytical performance, and offer the user a greater probability of correctly identifying positive or negative individuals. The challenge assumed to carry out the evaluation in the laboratory, and not just a documentary one. It has been a successful challenge, so that the leadership and stewardship of the InDRE have been strengthened in this pandemic event, both at the national and regional levels.
REFERENCES
European Centre for Disease Prevention and Control. An agency of the European Union. COVID-19 situation update worldwide. 2020. Available in: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases
Secretaría de Salud. Aviso epidemiológico. 27 de febrero del 2020.
Secretaría de Salud. Nota de Prensa # 077. Se confirma en México caso importado de coronavirus COVID-19. Secretaría de Salud. 28 de febrero de 2020 [Consultado el 13 de marzo de 2020].
World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. 2020. Available in: https://www.who.int/publications/i/item/laboratory-testing-of-2019-novel-coronavirus-(-2019-ncov)-in-suspected-human-cases-interim-guidance-17-january-2020
Organización Panamericana de Salud. Directrices de Laboratorio para la Detección y Diagnóstico de la Infección con el Nuevo Coronavirus 2019 (2019-nCoV). 2020. Disponible en: https://www.paho.org/es/documentos/directrices-laboratorio-para-deteccion-diagnostico-infeccion-con-nuevo-coronavirus-2019
Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020; 25 (3): 2000045. doi: 10.2807/1560-7917.ES.2020.25.3.2000045.
Secretaría de Salud. 057. México, sede del Taller de Diagnóstico y Detección por Laboratorio del nuevo coronavirus COVID-19. 2020. Disponible en: https://www.gob.mx/salud/prensa/057-mexico-sede-del-taller-de-diagnostico-y-deteccion-por-laboratorio-del-nuevo-coronavirus-covid-19
Guzmán-Bracho MC, Ramírez-Hernández JA, Rodríguez-Pérez ME, Viesca-Treviño C, Díaz-Quiñonez JA. Desde el ISET al InDRE. IV. Instituto de Diagnóstico y Referencia Epidemiológicos: nueva orientación, 1990-2012. Gac Méd Méx. 2020; 156 (2): 125-132.
Deeks JJ. Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001; 323 (7305): 157-162. doi: 10.1136/bmj.323.7305.157.
Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 2020; 20 (4): 411-412. doi: 10.1016/S1473-3099(20)30113-4.
Secretaría de Salud. Instituto de Diagnóstico y Referencia Epidemiológicos. Documentos de apoyo para el laboratorio. 2020. Disponible en: https://www.gob.mx/salud/documentos/documentos-de-apoyo-para-el-laboratorio?state=published
Instituto de Diagnóstico y Referencia Epidemiológicos. Protocolo de bioseguridad y biocustodia para la toma y manejo de muestras en el laboratorio para la enfermedad respiratoria viral. 2021. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/674821/Protocolo_Bioseguridad_Biocustodia_Enfermedad_Viral_InDRE_V8_12082021.pdf
Organización Mundial de la Salud. Orientaciones provisionales. Pruebas diagnósticas para el SARS-CoV-2. 2020. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/335830/WHO-2019-nCoV-laboratory-2020.6-spa.pdf
Chiappell F. Putative natural history of CoViD-19. bioinformation. 2020; 16 (5): 398-403. doi: 10.6026/97320630016398.
Dos Santos WG. Natural history of COVID-19 and current knowledge on treatment therapeutic options. Biomed Pharmacother. 2020; 129: 110493. doi: 10.1016/j.biopha.2020.110493.
WHO. Diagnostic testing for SARS-CoV-2 Interim guidance. 2020. Available in: https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2
Houlihan CF, Beale R. The complexities of SARS-CoV-2 serology. Lancet Infect Dis. 2020; 20 (12): 1350-1351. doi: 10.1016/S1473-3099(20)30699-X.
Secretaría de Salud. Comunicado de prensa. 28 de marzo del 2020. Secretaría de Salud informa. Disponible en: https://www.gob.mx/salud/prensa/secretaria-de-salud-informa-239153?idiom=es
Instituto de Diagnóstico y Referencia Epidemiológicos. Lineamientos para la vigilancia por laboratorio de la influenza y otros virus respiratorios. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/487580/LVL_Influenza_y_otros_virus_4T.pdf
Secretaría de Salud. Informe técnico reunión de expertos sobre uso de pruebas de laboratorio para identificar SARS-COV-2. 2020. Disponible en: https://coronavirus.gob.mx/wp-content/uploads/2020/06/Docto_InfTec-SARS-COV2_26jun2020.pdf
Secretaría de Salud. Criterios para la aceptación de pruebas moleculares para el diagnóstico de SARS-CoV-2 durante la contingencia de COVID-19 en México. 2020. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/547178/Criterios_para_la_aceptaci_n_de_pruebas_moleculares_para_el_diagn_stico_de_SARS-CoV-2.pdf
Secretaría de Salud. Evaluaciones provisionales en apoyo a la emergencia por la pandemia de la enfermedad por Coronavirus COVID 19. Informes de evaluación comparativa preliminar. 2022. Disponible en: https://www.gob.mx/salud/documentos/evaluaciones-provisionales-en-apoyo-a-la-emergencia-por-la-pandemia-de-la-enfermedad-covid-19?state=published
Instituto de Diagnóstico y Referencia Epidemiológicos. Laboratorios con reconocimiento por parte del InDRE, para realizar el diagnóstico de COVID 19, con fines de Vigilancia Epidemiológica. 2020. Disponible en: http://www.pjetam.gob.mx/doc/comunicado/laboratorios.pdf
World Health Organization. Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19): interim guidance, 12 February 2020. World Health Organization; 2020. Available in: https://apps.who.int/iris/handle/10665/331138. Licencia: CC BY-NC-SA 3.0 IGO
World Health Organization. Laboratory biosafety guidance related to coronavirus disease (COVID-19): interim guidance, 19 March 2020. World Health Organization; 2020. Available in: https://apps.who.int/iris/handle/10665/331500. Licencia: CC BY-NC-SA 3.0 IGO.
Full text
10.35366/106227